Skip to main content
. 2018 Jan 19;8:2002. doi: 10.3389/fimmu.2017.02002

Table 2.

B and T cell phenotypic characteristics [median (Q1, Q3) N] by HIV exposure.

Assay Median (Q1, Q3); N
p-Values
PHEU PHIV HUU PHIV:PHEU PHIV:HUU PHEU:HUU
CD4+: %CD38+ HLADR+ (activated T cells) 7.1 (5.0, 10.8); 38 7.9 (4.3, 10.8); 39 27.5 (22.9, 39.8); 4 0.87 0.002 0.002
CD4+: %IL17+ (mucosal inflammatory T cells) 2.8 (1.3, 5.9); 40 3.2 (1.6, 6.8); 42 0.7 (0.4, 1.2); 4 0.71 0.013 0.014
CD4+: %CD25+ FOXP3+ (regulatory T cells) 0.1 (0.0, 0.2); 38 0.1 (0.0, 0.2); 39 0.3 (0.2, 0.4); 4 0.43 0.11 0.06
CD4+: %IL10+ (regulatory T cells) 2.3 (1.0, 3.4); 40 2.0 (1.3, 3.2); 42 5.8 (5.2, 7.5); 4 0.71 0.004 0.014
CD4+: %TGFβ+ (regulatory T cells) 2.8 (1.6, 4.3); 40 2.5 (1.5, 5.2); 42 4.5 (2.6, 5.6); 4 0.85 0.51 0.37
CD8+: %CD38+ HLADR+ (activated T cells) 14.4 (10.8, 21.6); 37 13.1 (10.4, 19.3); 38 23.4 (21.9, 39.1); 4 0.62 0.030 0.043
CD8+: %IL17+ (mucosal inflammatory T cells) 4.8 (2.4, 11.1); 41 4.7 (2.2, 10.3); 43 3.3 (1.9, 5.1); 4 0.92 0.35 0.34
CD8+: %CD25+ FOXP3+ (regulatory T cells) 0.3 (0.1, 0.5); 37 0.2 (0.1, 0.4); 38 0.4 (0.3, 0.5); 4 0.21 0.16 0.46
CD8+: %IL10+ (regulatory T cells) 2.3 (1.5, 6.0); 41 1.8 (1.3, 5.6); 43 3.1 (2.0, 4.7); 4 0.66 0.61 0.81
CD8+: %TGFβ+ (regulatory T cells) 3.2 (2.0, 5.6); 41 3.8 (1.7, 8.2); 43 5.5 (2.9, 7.4); 4 0.73 0.70 0.40
CD19+: %CD10+ (immature B cells) 11.3 (6.6, 25.2); 41 11.9 (6.1, 23.9); 42 12.1 (10.1, 15.0); 4 0.89 0.82 0.97
CD19+: %C10− CD21+ CD27− (naive B cells) 25.5 (19.0, 33.3); 41 21.4 (11.5, 27.4); 42 51.4 (45.5, 60.2); 4 0.040 0.004 0.006
CD19+: %C10− CD21+ CD27+ (memory B cells) 32.4 (14.5, 52.5); 41 35.0 (17.3, 49.2); 42 15.4 (10.8, 18.2); 4 0.82 0.07 0.10
CD19+: %C10− CD21− CD27− (exhausted B cells) 31.6 (21.4, 48.9); 41 27.4 (20.7, 51.8); 42 21.9 (20.8, 23.3); 4 0.95 0.14 0.15
CD19+: %IL10+ (regulatory B cells) 2.5 (1.5, 3.3); 41 2.6 (1.7, 3.6); 39 5.3 (4.0, 7.5); 4 0.89 0.013 0.013
CD19+: %TGFβ+ (active B cells) 4.2 (2.0, 14.8); 41 3.7 (1.5, 11.2); 39 10.0 (4.9, 13.9); 4 0.61 0.24 0.52

Analyses were performed in perinatally HIV-infected infants (PHIV) and perinatally HIV-exposed uninfected (PHEU) data obtained at study entry; HIV-uninfected unexposed (HUU) had only one data set available at 6 months of life. Comparisons with p-values < 0.05 are bolded.